A randomized, prospective trial of ribavirin 400 mg/day versus 800 mg/day in combination with peginterferon alfa-2a in hepatitis C virus genotypes 2 and 3.

@article{Ferenci2008ARP,
  title={A randomized, prospective trial of ribavirin 400 mg/day versus 800 mg/day in combination with peginterferon alfa-2a in hepatitis C virus genotypes 2 and 3.},
  author={Peter Ferenci and Harald Brunner and Hermann Laferl and T M Scherzer and Andreas Maieron and Michael R Strasser and Christian Matzenauer and Harald Hofer and Martin G. Bischof and Rudolf E. Stauber and Michael Gschwantler and Petra Steindl-Munda and Katharina Staufer and Karin L{\"o}schenberger},
  journal={Hepatology},
  year={2008},
  volume={47 6},
  pages={
          1816-23
        }
}
UNLABELLED We compared the efficacy and tolerability of 24 weeks of treatment with ribavirin 800 mg/day (group A) or 400 mg/day (group B) plus peginterferon alfa-2a 180 mug/week in treatment-naive patients infected with hepatitis C virus (HCV) genotype 2 or 3. A total of 97 of 141 patients randomized to group A (68.8%, 95% confidence interval [CI] 60.5%-76.3%) and 90 of 141 patients randomized to group B (63.8; 95% CI 55.3%-71.7%) achieved a sustained virological response, defined as… CONTINUE READING
BETA

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 42 CITATIONS

KASL clinical practice guidelines: management of hepatitis C.

  • Clinical and molecular hepatology
  • 2016
VIEW 1 EXCERPT
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 20 REFERENCES

Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment.

  • Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • 2007